Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting

J Neurooncol. 2007 Jan;81(1):81-91. doi: 10.1007/s11060-006-9209-y. Epub 2006 Jul 21.


Although knowledge of molecular biology and cellular physiology has advanced at a rapid pace, much remains to be learned about delivering chemotherapy and antibodies across the blood-brain barrier (BBB) for the diagnosis and treatment of central nervous system (CNS) disease. A meeting, partially funded by an NIH R13 grant, was convened to discuss the state of the science, current knowledge gaps, and future directions in the delivery of drugs and proteins to the CNS, for the treatment of primary and metastatic brain tumors. Meeting topics included CNS metastases and the BBB, and chemoprotection and chemoenhancement in CNS disorders. The discussions regarding CNS metastases generated possibilities of chemoprotection as a means not only to decrease treatment-related toxicity but also to increase chemotherapy dose intensity. The increasing incidence of sanctuary brain metastasis from breast cancer, in part due to the difficulty of monoclonal antibodies (mAbs) such as herceptin to cross the BBB, was one of the most salient "take home" messages of the meeting.

Publication types

  • Congress
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use
  • Biological Transport
  • Blood-Brain Barrier / drug effects
  • Blood-Brain Barrier / physiology*
  • Brain Neoplasms / diagnosis
  • Brain Neoplasms / immunology
  • Brain Neoplasms / secondary
  • Brain Neoplasms / therapy*
  • Child
  • Child, Preschool
  • Drug Delivery Systems / methods*
  • Humans
  • Immunotherapy / methods*
  • Infant
  • Neoplasm Metastasis / diagnosis
  • Neoplasm Metastasis / immunology
  • Neoplasm Metastasis / therapy*
  • Neurotoxicity Syndromes / prevention & control


  • Antineoplastic Agents